Term umbilical cord blood, fully tested and processed, as the source of red blood cell transfusions for...

Area of Science:

• Neonatal Medicine
• Hematology
• Perinatal Biology

Background:

• Extremely-low-gestational-age neonates (ELGANs) are susceptible to severe morbidities, including retinopathy of prematurity (ROP) and bronchopulmonary dysplasia (BPD).
• Accumulating evidence links repeated transfusions of adult donor red blood cells (RBCs) to an increased risk of these morbidities in ELGANs.
• The underlying biological mechanisms may differ, with adult hemoglobin A potentially exacerbating ROP and adult RBCs' inflammatory properties possibly worsening BPD.

Purpose of the Study:

• To investigate the potential benefits of using fetal RBCs from umbilical cord blood as a transfusion alternative for anemic ELGANs.
• To evaluate whether fetal RBC transfusions can reduce the incidence or severity of common ELGAN morbidities.

Main Methods:

• Review of existing literature and research progress on the use of fetal versus adult donor RBC transfusions in ELGANs.
• Analysis of the biological rationale and proposed mechanisms linking RBC transfusion type to specific neonatal morbidities.

Main Results:

• The study reviews progress and findings from research exploring the use of fetal RBCs for ELGANs.
• Potential benefits of fetal RBCs include a more physiologically appropriate oxygen delivery and reduced inflammatory response compared to adult RBCs.

Conclusions:

• Fetal RBCs represent a promising, physiologically suitable alternative transfusion product for anemic ELGANs.
• Utilizing cord blood-derived fetal RBCs may mitigate the risk and severity of major neonatal morbidities in this vulnerable population.